Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + peginterferon alfa-2b with or without p53 SLP vaccine in platinum-resistant ovarian cancer
2010-023124-24Phase 2Completed
- Sponsor
- Leiden University Medical Center
- Start
- Nov 2010
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine, peginterferon alfa-2b and p53 peptide-loaded dendritic cell vaccine (University of Pittsburgh) in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Feasibility of combining gemcitabine with interferon alpha and p53-vaccine in patients with recurrent ovarian cancer. Started Nov 2010; status: completed.
02
Drugs
gemcitabinepeginterferon alfa-2bp53 peptide-loaded dendritic cell vaccine (University of Pittsburgh)
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2010-023124-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023124-24.